- Home
- FLUT vs ARGX Comparison
FLUT vs ARGX Comparison
Compare FLUT & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLUT
- ARGX
- Stock Information
- Founded
- FLUT 2016
- ARGX 2008
- Country
- FLUT United States
- ARGX Netherlands
- Employees
- FLUT N/A
- ARGX N/A
- Industry
- FLUT
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLUT
- ARGX Health Care
- Exchange
- FLUT NYSE
- ARGX Nasdaq
- Market Cap
- FLUT 41.0B
- ARGX 40.4B
- IPO Year
- FLUT N/A
- ARGX 2017
- Fundamental
- Price
- FLUT $228.70
- ARGX $589.15
- Analyst Decision
- FLUT Strong Buy
- ARGX Strong Buy
- Analyst Count
- FLUT 17
- ARGX 20
- Target Price
- FLUT $312.00
- ARGX $682.00
- AVG Volume (30 Days)
- FLUT 2.8M
- ARGX 314.1K
- Earning Date
- FLUT 03-04-2025
- ARGX 05-08-2025
- Dividend Yield
- FLUT N/A
- ARGX N/A
- EPS Growth
- FLUT N/A
- ARGX N/A
- EPS
- FLUT 0.24
- ARGX 12.78
- Revenue
- FLUT $14,048,000,000.00
- ARGX $2,248,205,000.00
- Revenue This Year
- FLUT $20.89
- ARGX $57.59
- Revenue Next Year
- FLUT $14.36
- ARGX $31.90
- P/E Ratio
- FLUT $952.00
- ARGX $43.61
- Revenue Growth
- FLUT 19.15
- ARGX 77.22
- 52 Week Low
- FLUT $174.03
- ARGX $352.77
- 52 Week High
- FLUT $299.73
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- FLUT 36.16
- ARGX 41.01
- Support Level
- FLUT $236.60
- ARGX $582.07
- Resistance Level
- FLUT $239.18
- ARGX $612.98
- Average True Range (ATR)
- FLUT 7.08
- ARGX 13.25
- MACD
- FLUT -0.03
- ARGX -0.34
- Stochastic Oscillator
- FLUT 10.18
- ARGX 40.89
About FLUT FLUTTER ENTERTAINMENT PLC
In 2016, Irish company Paddy Power merged with UK firm Betfair to form online gaming operator Flutter Entertainment. Today, Flutter has the top digital revenue share in the us, UK and Ireland, Australia, and many other countries. Some of its main brands are FanDuel in the us, Sky Betting & Gaming and Paddy Power in the UK and Ireland, Sportsbet (acquired by Paddy Power in 2009) in Australia, and Sisal in Italy. As of Dec. 31, 2023, the company offered products in over 100 countries and had 12.3 million average monthly users. In 2023, sports betting was 56% of revenue, online gaming 39%, and fantasy sports, horse racing, and other 5%.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.